Endoscopic Prediction of Achalasia: Putting the CART Before the CARS
- PMID: 40096578
- PMCID: PMC12163212
- DOI: 10.1111/nmo.70024
Endoscopic Prediction of Achalasia: Putting the CART Before the CARS
Abstract
Background and aims: Endoscopy can detect features indicative of esophageal dysmotility, but standardized approaches for diagnosing achalasia based on these findings remain limited. Recently, the CARS score was developed to address this gap. This study aimed to evaluate the diagnostic utility of endoscopy in identifying achalasia, using the STARD framework and current reference standards.
Methods: Adult patients with esophageal symptoms were prospectively enrolled from 2018 to 2023 and evaluated using endoscopy, esophageal manometry, FLIP panometry, and barium esophagram. The CARS score was assigned to endoscopic videos by two raters blinded to other clinical details. The diagnostic accuracy of the CARS score for predicting achalasia, based on Chicago Classification v4.0, was assessed through two interpretation methods: binary cutoffs for the total score and a classification tree model.
Results: 316 patients were included: 115 patients with achalasia (36%), 113 with normal motility (36%), and 88 with other manometric findings (28%). A CARS score ≥ 4 demonstrated 72% sensitivity and 99% specificity for achalasia, while a score ≥ 3 had 83% sensitivity and 96% specificity. The optimal classification tree had three levels (resistance score at the top, followed by anatomy and content scores, with hernia presence at the bottom) and had a sensitivity of 90% and a specificity 92% for achalasia.
Conclusion: Endoscopy can accurately identify achalasia with high specificity using the CARS score. While motility testing to confirm an achalasia diagnosis remains essential prior to therapy, a high CARS score may help in the early identification of achalasia, especially in settings where motility testing is not readily available.
Keywords: achalasia; dysphagia; endoscopy; esophageal motility.
© 2025 The Author(s). Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Conflict of interest statement
R.N.K.: Boston Scientific (Consulting), Medtronic (Consulting, Research Support). V.J.A.K.: Exact (Consulting, Advisory Board), Castle Biosciences (Consulting), Medtronic (Speaking, Consulting), Pentax (Consulting), Sebela/Braintree (Consulting, Advisory Board). J.E.P.: Sandhill Scientific/Diversatek (Consulting, Grant), Takeda (Speaking), AstraZeneca (Speaking), Medtronic (Speaking, Consulting, Patent, License), Torax/Ethicon (Speaking, Consulting), EndoGastric Solutions (Advisory Board), Phathom (Speaking, Consulting). D.A.C.: Medtronic (Speaking, Consulting, License); Diversatek (Consulting); Braintree (Consulting); Medpace (Consulting); Phathom Pharmaceuticals (Speaking; Consulting); Regeneron/Sanofi (Speaking). Other authors declare no conflicts to interest.
Figures
References
-
- Niebisch S., Hadzijusufovic E., Mehdorn M., et al., “Achalasia‐An Unnecessary Long Way to Diagnosis,” Diseases of the Esophagus 30, no. 5 (2017): 1–6. - PubMed
-
- Cameron A. J., Malcolm A., Prather C. M., and Phillips S. F., “Videoendoscopic Diagnosis of Esophageal Motility Disorders,” Gastrointestinal Endoscopy 49, no. 1 (1999): 62–69. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
